157 related articles for article (PubMed ID: 28396761)
1. Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years.
Shida Y; Hakariya T; Miyata Y; Sakai H
Clin Case Rep; 2017 Apr; 5(4):425-428. PubMed ID: 28396761
[TBL] [Abstract][Full Text] [Related]
2. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
[TBL] [Abstract][Full Text] [Related]
3. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
[TBL] [Abstract][Full Text] [Related]
4. [Intermittent androgen deprivation (IAD) for advanced prostate cancer. Why not the standard of therapy?].
Prapotnich D; Sánchez-Salas R; Cathelineau X; Stakhovskyi O; Rocha JE; Vallancien G
Arch Esp Urol; 2009 Nov; 62(9):689-94. PubMed ID: 19955592
[TBL] [Abstract][Full Text] [Related]
5. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
Abrahamsson PA
Eur Urol; 2010 Jan; 57(1):49-59. PubMed ID: 19683858
[TBL] [Abstract][Full Text] [Related]
6. Prevalence study of intermittent hormonal therapy of Prostate Cancer patients in Spain.
Bonfill-Cosp X; Auladell-Rispau A; Gich I; Zamora J; Saiz LC; Pijoan JI; Urreta I; Cordero JA
F1000Res; 2021; 10():1069. PubMed ID: 36330533
[No Abstract] [Full Text] [Related]
7. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.
Grossfeld GD; Small EJ; Carroll PR
Urology; 1998 Jan; 51(1):137-44. PubMed ID: 9457309
[TBL] [Abstract][Full Text] [Related]
8. A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
Kratiras Z; Konstantinidis C; Skriapas K
Int Braz J Urol; 2014; 40(1):3-15; discussion 15. PubMed ID: 24642162
[TBL] [Abstract][Full Text] [Related]
9. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
Klotz L; Toren P
Curr Oncol; 2012 Dec; 19(Suppl 3):S13-21. PubMed ID: 23355789
[TBL] [Abstract][Full Text] [Related]
11. Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the "New World Order"?
Shevach J; Sydes MR; Hussain M
Eur Urol Focus; 2019 Mar; 5(2):125-133. PubMed ID: 30803926
[TBL] [Abstract][Full Text] [Related]
12. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
[TBL] [Abstract][Full Text] [Related]
13. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
Niraula S; Le LW; Tannock IF
J Clin Oncol; 2013 Jun; 31(16):2029-36. PubMed ID: 23630216
[TBL] [Abstract][Full Text] [Related]
14. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.
Botrel TE; Clark O; dos Reis RB; Pompeo AC; Ferreira U; Sadi MV; Bretas FF
BMC Urol; 2014 Jan; 14():9. PubMed ID: 24460605
[TBL] [Abstract][Full Text] [Related]
15. Intermittent hormone therapy in nonmetastatic prostate cancer.
Opfermann KJ; Lai Z; Essenmacher L; Bolton S; Ager J; Forman JD
Clin Genitourin Cancer; 2006 Sep; 5(2):138-43. PubMed ID: 17026802
[TBL] [Abstract][Full Text] [Related]
16. Intermittent androgen deprivation: clinical experience and practical applications.
Wright JL; Higano CS; Lin DW
Urol Clin North Am; 2006 May; 33(2):167-79, vi. PubMed ID: 16631455
[TBL] [Abstract][Full Text] [Related]
17. [Hormonal therapy for prostate cancer: methods and prognosis].
Huang BX; Su HC; Cao WL; Sun FK
Zhonghua Nan Ke Xue; 2013 Sep; 19(9):815-9. PubMed ID: 24386861
[TBL] [Abstract][Full Text] [Related]
18. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.
Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
Eur Urol; 2013 Jan; 63(1):111-20. PubMed ID: 22857983
[TBL] [Abstract][Full Text] [Related]
19. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
Yu EY; Kuo KF; Gulati R; Chen S; Gambol TE; Hall SP; Jiang PY; Pitzel P; Higano CS
J Clin Oncol; 2012 May; 30(15):1864-70. PubMed ID: 22493411
[TBL] [Abstract][Full Text] [Related]
20. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
de Leval J; Boca P; Yousef E; Nicolas H; Jeukenne M; Seidel L; Bouffioux C; Coppens L; Bonnet P; Andrianne R; Wlatregny D
Clin Prostate Cancer; 2002 Dec; 1(3):163-71. PubMed ID: 15046691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
